en · de · es · fr · pt
aod-9604-notes.peptides3081.com › Guide › Handling, Analysis, And Quality Control — Hands-On Walkthrough

Handling, Analysis, And Quality Control — Hands-On Walkthrough

By Editorial Desk · published 2026-04-05 · last reviewed 2026-04-20 · Guide

anti-doping is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-04-20. Where a claim depends on a specific study, the study is described rather than over-claimed.

Handling, Analysis, and Quality Control

AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.

Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.

Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.

Background and Molecular Identity

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Aod-9604 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderLyophilized form; visual inspection
SolubilitySoluble in water and aqueous buffersDepends on pH, purity, and counterion
Typical storage-20 °C or below, desiccatedProtect from light; avoid repeated freeze-thaw after reconstitution
Common analytical methodReversed-phase HPLC and mass spectrometryPurity by HPLC; identity and mass by LC-MS or MALDI-TOF
Common synonymshGH fragment 176–191; AOD-9604Names vary in research and product labeling

Mechanism and Regulatory Status

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Related pages on this site

Research and Regulatory Status

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Reference notes

Leroy-Beaulieu was born in Rome. After spending her childhood in Italy where her father, Philippe Leroy, worked in the local film industry, she went to Paris at 16 to study drama against the advice of her parents; her father especially tried to keep her from pursuing a career that followed in his footsteps but was unsuccessful. After appearing on the stage, Leroy-Beaulieu made her screen début in Roger Vadim's 1983 comedy-drama film Surprise Party. The following year, she played Fauve Mistral in the 1984 mini-series version of Judith Krantz's novel Mistral's Daughter. In 1985, Leroy-Beaulieu played her first major screen role (and earned a nomination for the César Award for Most Promising Actress), playing the distraught mother in the Academy Award for Best Foreign Film-nominated comedy Trois hommes et un couffin (Three Men and a Cradle). The success of Coline Serreau's comedy helped her film career and a string of parts in costume films followed such films as Andrzej Wajda's Les Possédés in 1988, Philippe Le Guay's Les Deux Fragonard, and Robert Enrico's and Richard T. Heffron's La Révolution française (Mademoiselle Leroy-Beaulieu acted out the role of Charlotte Corday in the latter production), whose release in 1989 was timed to coincide with celebrations for the bi-centenary of the 1789 Revolution. Leroy-Beaulieu starred in the title role of the French film Natalia, which was screened at the 1988 Cannes Film Festival.

=== Multimodal methods === ImmunoStruct is a multimodal deep learning approach to immunogenicity prediction that fuses information from peptide–MHC sequence, structure, and biochemical properties. Rather than treating protein sequences as text alone, it combines complementary representations of the data to model interactions relevant to antigen presentation and T cell recognition. ImmunoStruct has demonstrated strong predictive performances on infectious disease epitopes (IEDB dataset) and human cancer neoepitopes (CEDAR dataset), and is generalizable to SARS-CoV-2 epitopes and cancer survival prediction. Its multimodal attention mechanism allows the model to differentially weight sequence, structural, and biochemical features for individual peptides, enabling analysis of structural determinants and peptide–MHC interactions associated with immunogenicity.

=== 2014–2021: The Seven-Headed Beast and Three Over Five line-ups === Prior to Fripp's retirement announcement, a band called Jakszyk, Fripp and Collins (subtitled "A King Crimson ProjeKct") had released an album called A Scarcity of Miracles in 2011. The band featured guitarist and singer Jakko Jakszyk (who had previously performed King Crimson material alongside former members with 21st Century Schizoid Band), Fripp and Mel Collins, with Tony Levin playing bass and Stick and Gavin Harrison drumming. At one point, Fripp referred to the band as "P7" (ProjeKct Seven). Unusually for a ProjeKct, it was based around "finely crafted" and "mid-paced" original songs derived from improvised sessions. In September 2013, Fripp announced King Crimson's return to activity with a "very different reformation to what has gone before: seven players, four English and three American, with three drummers". He cited several reasons to make a comeback, varying from the practical to the whimsical: "I was becoming too happy. Time for a pointed stick." The new line-up drew from both the previous line-up (retaining Fripp, Levin, Harrison and Mastelotto) and the Scarcity of Miracles project (Jakszyk and Collins), with Guitar Craft alumnus and former R.E.M./Ministry drummer Bill Rieflin as the seventh member. Belew was not asked to take part, thus ending his 32-year tenure in King Crimson. This version of the group took on the nickname of "the Seven-Headed Beast".

Sources: en.wikipedia.org

Reference notes

MBInfo: Sarcomere[link removed] MBInfo: Contractile Fiber Muscular Tissues Videos Histology image: 21601ooa – Histology Learning System at Boston University - "Ultrastructure of the Cell: sarcoplasm of skeletal muscle" MedicalMnemonics.com: 50 379 107 Images created by antibody to striations Archived 2020-12-22 at the Wayback Machine Muscle Contraction for dummies Model representation of the sarcomere

== Career == After completing his doctorate, Al-Fawzan was appointed as a teacher at the Ma'had al-'Ilmī (Institute of Knowledge) at the Imam Muhammad ibn Saud Islamic University in Riyadh. He subsequently taught at Kullīyat al-Sharī'a (The College of Sharia), then transferred to teach in the postgraduate program at Kullīyat Uṣūl al-Dīn (College of Fundamentals of Religion), then at the Ma'had al-'Ālī li al-Qaḍā (Higher Institute of Judiciary), where he was later appointed director. He later served as the head of Saudi Arabia's Supreme Court of Justice before returning to teaching following the conclusion of his tenure. As of 2013, he was appointed as a member of the Council of Senior Scholars, Saudi Arabia's highest religious body, which directly advises the King of Saudi Arabia. He is also currently a member of the fiqh council in Mecca, which is affiliated with the Muslim World League, and of the Permanent Committee for Scholarly Research and Ifta, a subcommittee of the Council of Senior Scholars responsible for issuing legal opinions (fatwas) in Islamic jurisprudence (fiqh) and preparing research papers for the Council. Al-Fawzan serves on the Supervisory Committee for Preachers during Hajj and is an imam, khatib and teacher at the Prince Mutaib bin Abdulaziz Al Saud Mosque in Riyadh. He is one of the scholars featured on the Nūr 'Alā al-Darb radio program, described as one of the oldest and most famous programs broadcast on the Quran radio channel, where senior scholars answer questions and issue fatwas.

== Society and culture == In both legend and mythology, favism has been known since antiquity. The priests of various Greco-Roman era cults were forbidden to eat or even mention beans, and Pythagoras had a strict rule that to join the society of the Pythagoreans one had to swear off beans. This ban was supposedly because beans resembled male genitalia. It is possible that this was because of a belief that beans and humans were created from the same material.

Sources: en.wikipedia.org

Frequently asked questions

How is AOD9604 typically stored?

Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.

What methods confirm AOD9604 identity?

Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.

Is AOD9604 the same as human growth hormone?

No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.

What is AOD-9604?

It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.

Network